Principal Financial Group’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,668
| Closed | -$481K | – | 2272 |
|
|
2025
Q4 | $481K | Sell |
6,668
-1,076
| -14% | -$69.5K | ﹤0.01% | 2050 |
|
|
2025
Q3 | $337K | Sell |
7,744
-372
| -5% | -$15K | ﹤0.01% | 2109 |
|
|
2025
Q2 | $230K | Sell |
8,116
-954
| -11% | -$28.4K | ﹤0.01% | 2114 |
|
|
2025
Q1 | $268K | Sell |
9,070
-380
| -4% | -$11.8K | ﹤0.01% | 2012 |
|
|
2024
Q4 | $275K | Sell |
9,450
-590
| -6% | -$24.7K | ﹤0.01% | 2051 |
|
|
2024
Q3 | $461K | Sell |
10,040
-6,484
| -39% | -$281K | ﹤0.01% | 1973 |
|
|
2024
Q2 | $675K | Sell |
16,524
-1,103
| -6% | -$31.6K | ﹤0.01% | 1899 |
|
|
2024
Q1 | $450K | Sell |
17,627
-1,858
| -10% | -$29.1K | ﹤0.01% | 2008 |
|
|
2023
Q4 | $176K | Sell |
19,485
-1,461
| -7% | -$9.77K | ﹤0.01% | 2189 |
|
|
2023
Q3 | $134K | Buy |
20,946
+3,443
| +20% | +$29.7K | ﹤0.01% | 2228 |
|
|
2023
Q2 | $194K | Buy |
17,503
+2,013
| +13% | +$25.3K | ﹤0.01% | 2189 |
|
|
2023
Q1 | $238K | Buy |
15,490
+3,460
| +29% | +$76.1K | ﹤0.01% | 2140 |
|
|
2022
Q4 | $267K | Buy |
12,030
+1,333
| +12% | +$19.9K | ﹤0.01% | 2133 |
|
|
2022
Q3 | $175K | Buy |
+10,697
| New | +$205K | ﹤0.01% | 2233 |
|
|
2021
Q4 | – | Sell |
-46,734
| Closed | -$1.15M | – | 2613 |
|
|
2021
Q3 | $1.15M | Sell |
46,734
-1,498
| -3% | -$32.6K | ﹤0.01% | 1976 |
|
|
2021
Q2 | $1.19M | Buy |
48,232
+24,706
| +105% | +$575K | ﹤0.01% | 2002 |
|
|
2021
Q1 | $513K | Buy |
23,526
+1,758
| +8% | +$43K | ﹤0.01% | 2144 |
|
|
2020
Q4 | $556K | Buy |
+21,768
| New | +$635K | ﹤0.01% | 2087 |
|
Other funds holding RNAM
Principal Financial Group's RNAM Position: Q1 2026 in Review
Principal Financial Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 6,668 shares — an estimated $481K sold.
Principal Financial Group first reported a position in RNAM in Q4 2020 and held it in 18 quarters. The position peaked at $1.19M in Q2 2021. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Principal Financial Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Principal Financial Group sold 6,668 Avidity Biosciences shares in Q1 2026, an estimated $481K.
- Principal Financial Group first reported a position in Avidity Biosciences in Q4 2020 and held it in 18 quarters.
- Principal Financial Group's Avidity Biosciences position peaked at $1.19M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.